Our key findings revealed a surprising reduction in Aβ oligomer levels in Alzheimer’s disease (AD) and subjective cognitive decline (SCD) patients compared to healthy controls—challenging earlier reports that suggested increased levels. Importantly, the study uncovered a correlation between plasma and cerebrospinal fluid (CSF) oligomer concentrations, linking impaired Aβ clearance to the ApoE ε4 risk factor.

These results provide novel insights into Alzheimer’s disease pathophysiology and highlight the potential of blood-based Aβ oligomers as biomarkers for early diagnosis and drug development.

We thank Prof. Oliver Peters and the DELCODE team at DZNE for their outstanding collaboration in making this study possible.

Read the full paper here.

Aβ misfolding and aggregation, along with Tau protein tangles, are hallmarks of Alzheimer’s disease progression. Until now, detecting these markers in a non-invasive manner has posed a challenge. In this study, we hypothesized that Aβ aggregates might be cleared from the brain and body into the gut, allowing for measurable detection in fecal samples.

Using sFIDA technology, we were able to precisely determine Aβ aggregate concentrations in fecal samples from 26 Alzheimer’s patients and 31 healthy controls. Our technology, designed for ultrasensitive detection of protein aggregates, revealed significantly elevated Aβ concentrations in AD patients compared to healthy controls, achieving a specificity of 90.3%.

This highlights the power of our sFIDA technology, uniquely capable of detecting minute amounts of protein aggregates with exceptional accuracy. These findings suggest that Aβ aggregates in feces could serve as a non-invasive biomarker for Alzheimer’s disease, marking an important step forward in diagnostic capabilities. Ongoing research will explore whether these aggregates are secreted via the liver and bile or originate directly from the enteric nervous system.

Find the paper here.

The study found that IAPP oligomerisation levels in blood plasma were highest among individuals with T2D who were not undergoing insulin therapy and did not exhibit late-stage complications. In contrast, healthy controls showed the lowest levels of IAPP oligomerisation. Notably, in patients with T2D, higher IAPP oligomerisation levels were linked to longer disease duration, suggesting a correlation between IAPP aggregation and the progression of T2D.

These results bolster the hypothesis that IAPP aggregation may be a driving factor in the development and progression of T2D, rather than merely a consequence of the disease. This challenges the conventional view that T2D development primarily results from insulin resistance leading to pancreatic β-cell exhaustion.

The use of sFIDA technology has proven crucial in unveiling these insights, demonstrating its potential to deepen our understanding of T2D pathology. Further research, including comparative analyses with primary tissues, is needed to solidify these findings and explore the therapeutic potential of targeting IAPP oligomers in T2D management.

Stay connected with attyloid for more updates as we continue to push the boundaries of diabetes research using innovative technologies like sFIDA.

Find the paper here.

At attyloid, we are eager to showcase how our proprietary sFIDA technology can enhance your preclinical and clinical development of CNS drugs. Our technology offers cutting-edge solutions for quantifying biomarkers and advancing therapeutic strategies, making it an invaluable tool in the biotech field.

We look forward to meeting you at BIO, where we can discuss in person how attyloid’s innovations can support and accelerate your projects in the CNS drug development arena. See you there!

June 3-6, 2024 in San Diego

https://convention.bio.org

]]> https://attyloid.com/2024/05/10/meet-us-at-bio-international-june-3-6-2024-in-san-diego/feed/ 0 https://attyloid.com/2024/05/10/attyloids-sfida-technology-sheds-light-on-the-pathophysiological-role-of-a%ce%b2-oligomers/ https://attyloid.com/2024/05/10/attyloids-sfida-technology-sheds-light-on-the-pathophysiological-role-of-a%ce%b2-oligomers/#respond Fri, 10 May 2024 12:09:35 +0000 https://attyloid.com/?p=1974 We are very happy to announce that our latest research paper, titled “Aβ oligomers peak in early stages of Alzheimer’s disease preceding Tau pathology”, has been published in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM).

Our research sheds light on the pivotal role of soluble Aβ oligomers in the development of Alzheimer’s disease (AD), focusing on their quantitative distribution and chronological sequence within the AD continuum. By analyzing 526 participants from the DELCODE study, our findings underscore the presence of Aβ oligomers peaking in early disease stages, specifically in individuals with subjective cognitive decline and mild cognitive impairment.

This study leverages attyloid’s proprietary sFIDA technology to measure Aβ and Tau oligomer titers in biofluids, presenting novel insights into the pathophysiology of AD. We extend our deepest gratitude to our collaborators across clinics, academia and industry. This achievement highlights the importance of our collective effort and the synergistic benefits of combining diverse expertise to advance our understanding and treatment of Alzheimer’s disease.

Find the paper here.

With a focus on drug discovery for proteopathic neurodegenerative diseases, the meeting brings together experts from discovery companies, service providers and academic innovators in the field of neurodegenerative diseases e.g. Alzheimer’s disease, Parkinson’s disease, FTD and ALS.

www.neuro4d.com

Alzheimer’s disease and other neurodegenerative disorders stand as formidable challenges in health research today. This symposium aims to create an interdisciplinary platform focusing on the pathology of Alzheimer’s, particularly amyloid aggregation. The event will gather both emerging and renowned experts across basic and clinical sciences, facilitating a rich exchange of current research, new diagnostic methods, and therapeutic approaches.

Date: December 05-07, 2023
Venue: ‘Haus der Universität’, Düsseldorf, Germany

Program 5th Düsseldorf-Jülich Symposium